106,95 €
106,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
53 °P sammeln
106,95 €
106,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
53 °P sammeln
Als Download kaufen
106,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
53 °P sammeln
Jetzt verschenken
106,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
53 °P sammeln
  • Format: ePub

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors,…mehr

  • Geräte: eReader
  • mit Kopierschutz
  • eBook Hilfe
  • Größe: 9.84MB
Produktbeschreibung
Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more.

Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death.

  • Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology
  • Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity
  • Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Dr. Imteyaz Qamar is working as an assistant professor at School of biotechnology, Gautam Buddha University, Greater Noida, India. His area on interest is Stress biology, and Cancer Genetics

He earned his Ph.D. in Molecular Endocrinology from Chonnam National University, South Korea with an emphasis on gene regulation and physiological function of an androgen receptor corepressor-19kD using mice model. He has written various manuscripts, grants, progress reports, pre-IND protocols, animal protocols and published in well reputed international journals. He has also received various awards such as Brain Korea-21 Best Research presenter award 2007, Bharath Vikas award 2016, Young Scientist Award 2017 & 2019, STE meritorious award 2019 etc. He serves as a member of editorial boards of various peer reviewed journals. He is also a member of the endocrinology society, United States of America (USA).

Prof. Pawan Kumar Maurya is Dean, School of Life Long Learning & Head of Department of Biochemistry, Central University of Haryana, India. He has done a PhD from the University of Allahabad (A Central University), India & post-doctoral training from Universidade Federal de Sao Paulo-UNIFESP, Brazil; Taipei Medical University (TMU) and National Taiwan University (NTU), Taiwan. He has more than 14 years of teaching and research experience. He is working on biochemical diagnostics, nanomedicine, and clinical biochemistry. He has published over 75 research articles in reputed journals. He has also edited of six books published from Elsevier, USA and Springer-Nature, Singapore. He is recipient of prestigious fellowships: Science without Borders (Government of Brazil) and National Science Council, Taiwan.